During menopausal transition women develop vasomotor and psychosomatic symptoms. These symptoms stem both from estrogen deprivation and hypothalamic-pituitary system ageing. Melatonin is a powerful hormonal adaptogen, working at every level of reproductive system, down to receptor level. To measure its effect on climacteric symptoms, we enrolled 55 women between 45 and 65 y.o. All participants took 3 mg of melatonin - Melaxen (Unipharm, Inc.) for 3 months. During the therapy we observed marked reduction of symptoms from 40.96 to 21.36 (47.92%) on Greene Climacteric Scale and sleep improvement from 16.60±4.03 to 7.33±1.95 on Pittsburgh Sleep Quality Index. Melatonin 3 mg is an effective method of climacteric symptoms therapy.